Physician profile
Thomas Christopher Gray
NPI 1174898373
$1,979.37
in general payments reported to CMS, 2019-2025
26 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $588 · 2021: $347 · 2022: $87.18 · 2023: $205 · 2024: $142 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $811.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $477.45 | 2020-2021 | |
| Abbvie INC. | $347.75 | 2021-2025 | |
| Novo Nordisk INC | $146.86 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $100.68 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.14 | 2019-2022 | |
| Astellas Pharma US INC | $75.59 | 2019-2020 | |
| Corcept Therapeutics | $70.96 | 2025 | Korlym |
| Amphastar Pharmaceuticals, INC. | $65.65 | 2024-2025 | |
| Exact Sciences Corporation | $63.96 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $61.61 | 2020-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $57.80 | 2019-2021 | |
| Amgen INC. | $56.23 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $50.27 | 2020-2025 | Breztri |
| E.R. Squibb & Sons, L.L.C. | $46.57 | 2024-2025 | Eliquis |
| Pfizer INC. | $45.81 | 2020-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $32.57 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.18 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $26.57 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $26.41 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.09 | 2021 | |
| Dexcom, INC. | $20.07 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.63 | 2025 | Xifaxan |
| Abbott Laboratories | $14.21 | 2025 | Freestyle Libre 3 |
| Exeltis, USA INC. | $13.85 | 2025 | Slynd |
| Sanofi-Aventis U.S. LLC | $13.33 | 2022 | |
| Travere Therapeutics, INC. | $5.13 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.